Hodgkin’s ap­proval

Pharmacy Daily - - NEWS -

MSD has an­nounced its anti-PD-1 im­munother­apy can­cer treat­ment Keytruda (pem­brolizumab) has been ap­proved by the Ther­a­peu­tic Goods Ad­min­is­tra­tion (TGA) for the treat­ment of adults with re­lapsed or re­frac­tory clas­si­cal Hodgkin Lym­phoma (CHL).

Hae­ma­tol­o­gists have wel­comed the new use for Keytruda, not­ing that 13% of pa­tients with this form of lym­phoma die within five years of di­ag­no­sis.

“Im­munother­apy with Keytruda rep­re­sents a turn­ing point in how we treat pa­tients with cHL who have ex­hausted other treat­ment op­tions,” said Prof Mark Hertzberg, Head of Depart­ment of Clin­i­cal Hae­ma­tol­ogy, Prince of tales Hospi­tal in Sydney.

“Pem­brolizumab has been shown to pro­vide deep and pro­longed re­mis­sions in pa­tients with cHL who have failed stan­dard ther­a­pies,” Hertzberg said.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.